GTAM
ALXN

Global Trust Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Global Trust Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-55
Closed -$5K – 463
2018
Q4 		$5K Hold
55
– – ﹤0.01% 312
2018
Q3 		$8K Buy
55
+31
+129% +$3.89K 0.01% 322
2018
Q2 		$3K Hold
24
– – ﹤0.01% 359
2018
Q1 		$3K Hold
24
– – ﹤0.01% 348
2017
Q4 		$3K Buy
+24
New +$2.92K ﹤0.01% 363

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Global Trust Asset Management's ALXN Position: Q1 2019 in Review

Global Trust Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 55 shares — an estimated $5K sold.

Global Trust Asset Management first reported a position in ALXN in Q4 2017 and held it in 5 quarters. The position peaked at $8K in Q3 2018. 611 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

  • Global Trust Asset Management reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Global Trust Asset Management sold 55 Alexion Pharmaceuticals shares in Q1 2019, an estimated $5K.
  • Global Trust Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 5 quarters.
  • Global Trust Asset Management's Alexion Pharmaceuticals position peaked at $8K in Q3 2018.
  • 611 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Global Trust Asset Management's 13F filing for Q1 2019, filed 5 Apr 2019.